BACKGROUND: Measurement of fractional nitric oxide (NO) concentration in exhaled breath (Fe(NO)) is a quantitative, noninvasive, simple, and safe method of measuring airway inflammation that provides a complementary tool to other ways of assessing airways disease, including asthma. While Fe(NO) measurement has been standardized, there is currently no reference guideline for practicing health care providers to guide them in the appropriate use and interpretation of Fe(NO) in clinical practice. PURPOSE: To develop evidence-based guidelines for the interpretation of Fe(NO) measurements that incorporate evidence that has accumulated over the past decade. METHODS: We created a multidisciplinary committee with expertise in the clinical care, clinical science, or basic science of airway disease and/or NO. The committee identified important clinical questions, synthesized the evidence, and formulated recommendations. Recommendations were developed using pragmatic systematic reviews of the literature and the GRADE approach. RESULTS: The evidence related to the use of Fe(NO) measurements is reviewed and clinical practice recommendations are provided. CONCLUSIONS: In the setting of chronic inflammatory airway disease including asthma, conventional tests such as FEV(1) reversibility or provocation tests are only indirectly associated with airway inflammation. Fe(NO) offers added advantages for patient care including, but not limited to (1) detecting of eosinophilic airway inflammation, (2) determining the likelihood of corticosteroid responsiveness, (3) monitoring of airway inflammation to determine the potential need for corticosteroid, and (4) unmasking of otherwise unsuspected nonadherence to corticosteroid therapy.
BACKGROUND: Measurement of fractional nitric oxide (NO) concentration in exhaled breath (Fe(NO)) is a quantitative, noninvasive, simple, and safe method of measuring airway inflammation that provides a complementary tool to other ways of assessing airways disease, including asthma. While Fe(NO) measurement has been standardized, there is currently no reference guideline for practicing health care providers to guide them in the appropriate use and interpretation of Fe(NO) in clinical practice. PURPOSE: To develop evidence-based guidelines for the interpretation of Fe(NO) measurements that incorporate evidence that has accumulated over the past decade. METHODS: We created a multidisciplinary committee with expertise in the clinical care, clinical science, or basic science of airway disease and/or NO. The committee identified important clinical questions, synthesized the evidence, and formulated recommendations. Recommendations were developed using pragmatic systematic reviews of the literature and the GRADE approach. RESULTS: The evidence related to the use of Fe(NO) measurements is reviewed and clinical practice recommendations are provided. CONCLUSIONS: In the setting of chronic inflammatory airway disease including asthma, conventional tests such as FEV(1) reversibility or provocation tests are only indirectly associated with airway inflammation. Fe(NO) offers added advantages for patient care including, but not limited to (1) detecting of eosinophilic airway inflammation, (2) determining the likelihood of corticosteroid responsiveness, (3) monitoring of airway inflammation to determine the potential need for corticosteroid, and (4) unmasking of otherwise unsuspected nonadherence to corticosteroid therapy.
Authors: Richard S Hewitt; Andrew D Smith; Jan O Cowan; John C Schofield; G Peter Herbison; D Robin Taylor Journal: J Asthma Date: 2008-03 Impact factor: 2.515
Authors: Peter J Barnes; Raed A Dweik; Arthur F Gelb; Peter G Gibson; Steven C George; Hartmut Grasemann; Ian D Pavord; Felix Ratjen; Philip E Silkoff; D Robin Taylor; Noe Zamel Journal: Chest Date: 2010-09 Impact factor: 9.410
Authors: Erika Garcia; Yue Zhang; Edward B Rappaport; Kiros Berhane; Patrick Muchmore; Philip E Silkoff; Noa Molshatzki; Frank D Gilliland; Sandrah P Eckel Journal: Eur Respir J Date: 2020-07-02 Impact factor: 16.671
Authors: Anne M Fitzpatrick; Susan T Stephenson; Milton R Brown; Khristopher Nguyen; Shaneka Douglas; Lou Ann S Brown Journal: J Allergy Clin Immunol Pract Date: 2016-09-21
Authors: Ricardo L M Duarte; Marcelo F Rabahi; Tiago S Oliveira-E-Sá; Flavio J Magalhães-da-Silveira; Fernanda C Q Mello; David Gozal Journal: Lung Date: 2019-01-02 Impact factor: 2.584
Authors: Eric Karlin; Tebeb Gebretsadik; R Stokes Peebles; Tina V Hartert; Emily W Langley; Donald H Arnold Journal: Ann Allergy Asthma Immunol Date: 2014-12-06 Impact factor: 6.347
Authors: Stephanie Lovinsky-Desir; Kyung Hwa Jung; Andrew G Rundle; Lori A Hoepner; Joshua B Bautista; Frederica P Perera; Steven N Chillrud; Matthew S Perzanowski; Rachel L Miller Journal: Environ Res Date: 2016-09-29 Impact factor: 6.498
Authors: Frank S Cikach; Adriano R Tonelli; Jarrod Barnes; Kelly Paschke; Jennie Newman; David Grove; Luma Dababneh; Sihe Wang; Raed A Dweik Journal: Chest Date: 2014-03-01 Impact factor: 9.410